Empagliflozin Desbromo Impurity

Empagliflozin Desbromo Impurity is a process-related impurity formed during the synthesis of empagliflozin when a bromine atom, normally present in a key intermediate, is missing. Essentially, it is the “desbromo” version of empagliflozin, meaning the molecule is identical except that the bromine substituent is absent. This impurity is important to monitor because its presence can affect the purity, efficacy, and regulatory compliance of the final drug product. Analytical methods like HPLC or LC-MS are typically used to detect and quantify it.